| Name | Title | Contact Details |
|---|---|---|
Andy Stadheim |
Vice President, Head of Product Development / Antibody Discovery | Profile |
Dipal Doshi |
President and Chief Executive Officer | Profile |
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
Fytokem Products Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
Reprocell is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aderans Research Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.